ROSIGLITAZONE VS TELMISARTAN ON THE MODIFICATION OF INSULIN-RESISTANCE CKD

罗格列酮与替米沙坦对胰岛素抵抗 CKD 的改变

• 批准号: 7717920
• 负责人: BRYAN David MYERS
• 金额: $ 0.1万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717920
• 关键词: 2,4-thiazolidinedione; Address; Angiotensin II Receptor; Attenuated; Chronic Kidney Failure; Computer Retrieval of Information on Scientific Projects Database; Development; Disease Outcome; Dyslipidemias; Funding; Grant; Guidelines; Hypertension; Inflammation; Institution; Insulin Resistance; Intervention; Kidney Diseases; Modification; Morbidity - disease rate; Patients; Pilot Projects; Prevalence; Property; Rate; Research; Research Personnel; Resources; Risk Factors; Source; Thiazolidinediones; United States National Institutes of Health; base; cardiovascular risk factor; mortality; novel; outcome forecast; rosiglitazone; telmisartan

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The prevalence of chronic kidney disease (CKD) is growing at an alarming rate and discovering when common complications develop including insulin resistance is critical to our ability to anticipate morbidity and mortality and treat patients more effectively. Insulin resistance has been associated with the development of cardiovascular risk factors including hypertension, dyslipidemia, inflammation and perhaps accelerated progression of CKD. Such risk factors in the setting of early renal disease merit a pilot study of a potential intervention to reverse insulin resistance. There are no specific guidelines included in Kidney Disease Outcome Quality Initiative (K-DOQI) that address treatment of insulin resistance due to CKD. The demonstration that thiazolidinedione (TZD) therapy or that telmisartan, an angiotensin II receptor blocker with novel properties, reverses insulin resistance in CKD could provide a basis for long-term therapy that attenuates the complications and prognosis of CKD.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 慢性肾脏疾病（CKD）的患病率正在以惊人的速度增长，并发现何时出现常见并发症，包括胰岛素抵抗，对于我们预期发病率和死亡率并更有效地治疗患者的能力至关重要。 胰岛素抵抗与心血管危险因素的发展有关，包括高血压，血脂异常，炎症以及CKD的加速进展。 在早期肾脏疾病的情况下，此类危险因素值得一研究，对逆转胰岛素抵抗的潜在干预措施进行了试点研究。 肾脏疾病结果质量质量倡议（K-DOQI）中没有任何特定指南，该指南涉及CKD引起的胰岛素抵抗的处理。 噻唑烷二酮（TZD）疗法或具有新颖性质的血管紧张素II受体阻滞剂的硫代授酯二酮（TZD）治疗的证明，CKD中的胰岛素抵抗可以为长期治疗提供抑制作用，从而减轻CKD的并发症和预后。